Results 81 to 90 of about 44,894 (310)

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

CYP2D6 Metabolizer Status and Mortality in Metoprolol Users. [PDF]

Clin Transl Sci
ABSTRACT Numerous pharmacogenomic (PGx) associations of pharmacokinetics and pharmacodynamics of commonly prescribed medications have been reported. Yet, the evidence supporting their association on survival remains underexamined. We sought to investigate the CYP2D6‐metoprolol association and determine whether the established variability in drug ...
de Denus S, Oussaïd E, Meloche M, Bertrand AX, Leclair G, Cyr MC, Jutras M, Gaulin MJ, Mongrain I, Busseuil D, Tardif JC, Dubé MP.   +11 more
europepmc   +2 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy

Clinical pharmacology and therapy, 2019
Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety.
Jacob T. Brown, Jeffrey R. Bishop, K. Sangkuhl, E. Nurmi, Daniel J. Mueller, Jean C. Dinh, A. Gaedigk, T. Klein, Kelly E. Caudle, J. T. McCracken, Jose de Leon, J. S. Leeder   +11 more
semanticscholar   +1 more source

Cholic Acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice [PDF]

Drug Metabolism and Disposition, 2017
Cytochrome P450 2D6 (CYP2D6) is a major drug-metabolizing enzyme, but the factors governing transcriptional regulation of its expression remain poorly understood. Based on previous reports of small heterodimer partner (SHP) playing an important role as a transcriptional repressor of CYP2D6 expression, here we investigated how a known upstream regulator
Xian, Pan, Rebecca, Kent, Kyoung-Jae, Won, Hyunyoung, Jeong   +3 more
openaire   +2 more sources

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

A Review on the Potential of Application of CRISPR/Cas9 Technology in CYP3A4 and CYP2D6 Genes: A Way to Move Forward in Identifying New Drug Targets

ASM Science Journal, 2022
The cytochrome P450 (CYP) enzymes are of a ubiquitous heme–thiolate proteins family that plays an important role within the biotransformation of endogenous molecules and xenobiotics as today’s market is bio-transformed through CYP-mediated metabolism ...
Fazleen Haslinda Mohd Hatta, Ahmad Azani Othman, Rosmadi Mohd Yusoff, Siti Norsyuhada Nor Azam, Aliah Zuhairah Ali Hassan   +4 more
doaj   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras Serrano, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network

Pharmacogenomics and Personalized Medicine, 2020
Benjamin Q Duong,1 Meghan J Arwood,2 J Kevin Hicks,3 Amber L Beitelshees,4 Francesco Franchi,5 John T Houder,2 Nita A Limdi,6 Kelsey J Cook,7,8 Aniwaa Owusu Obeng,9 Natasha Petry,10 Sony Tuteja,11 Amanda R Elsey,2 Larisa H Cavallari,2 Kristin Wiisanen2 ...
Duong BQ, Arwood MJ, Hicks JK, Beitelshees AL, Franchi F, Houder JT, Limdi NA, Cook KJ, Owusu Obeng A, Petry N, Tuteja S, Elsey AR, Cavallari LH, Wiisanen K   +13 more
doaj  

CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study

Malaria Journal, 2018
Background CYP2D6 pathway mediates the activation of primaquine into active metabolite(s) in hepatocytes. CYP2D6 is highly polymorphic, encoding CYP2D6 isoforms with normal, reduced, null or increased activity.
Larissa W. Brasil, Fernanda Rodrigues-Soares, Ana B. Santoro, Anne C. G. Almeida, Andrea Kühn, Rajendranath Ramasawmy, Marcus V. G. Lacerda, Wuelton M. Monteiro, Guilherme Suarez-Kurtz   +8 more
doaj   +1 more source